- Henry Schein, Inc. recently reported fourth-quarter 2025 results showing sales of US$3,437 million and net income of US$101 million, alongside full-year 2025 sales of US$13.18 billion and net income of US$398 million, while also booking a US$15 million intangible asset impairment and completing a sizeable share repurchase program.
- At the same time, Henry Schein One introduced new Dentrix Ascend cloud packages built on an integrated, AI-enabled platform and the company issued 2026 sales growth guidance of 3% to 5%, underscoring its emphasis on higher-margin digital solutions and recurring software revenue.
- We’ll now examine how Henry Schein’s stronger earnings and expanded Dentrix Ascend platform may influence the existing investment narrative around digital growth.
AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Henry Schein Investment Narrative Recap
To own Henry Schein, you need to believe its mix shift toward higher margin software, specialty products and services can matter more than slow headline revenue growth and tight pricing in core distribution. The latest results and 2026 sales growth guidance of 3% to 5% support the idea of steady, rather than spectacular, progress, while the biggest near term risk still looks tied to margin pressure from competitive pricing and customer bargaining power, which this news does not materially change.
The Dentrix Ascend relaunch is the clearest link to the current digital growth story, as it expands Henry Schein One’s cloud offering into tiered, AI enabled packages. If that helps deepen recurring software revenue and stickier customer relationships, it could gradually offset some of the margin risk in traditional distribution, though investors will still want to watch how quickly these new packages translate into meaningful economic contribution.
Yet even with the digital story improving, investors should be aware that continued competitive pricing and customer pressure on margins could still...
Read the full narrative on Henry Schein (it's free!)
Henry Schein’s narrative projects $14.4 billion revenue and $614.4 million earnings by 2028. This requires 4.0% yearly revenue growth and about a $225 million earnings increase from $389.0 million today.
Uncover how Henry Schein's forecasts yield a $83.21 fair value, a 7% upside to its current price.
Exploring Other Perspectives
Some bullish analysts were already assuming revenue above US$14.9 billion and earnings near US$660 million by 2029, so compared with the cybersecurity disruption risk they highlight, this quarter’s digital and guidance updates could either reinforce that optimism or prompt a rethink, depending on how you interpret the new Dentrix Ascend push.
Explore 2 other fair value estimates on Henry Schein - why the stock might be worth over 2x more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Henry Schein research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Henry Schein research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Henry Schein's overall financial health at a glance.
No Opportunity In Henry Schein?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
- Find 46 companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com